CareDx Inc (NASDAQ:CDNA) CFO Michael Brian Bell sold 16,355 shares of the company’s stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $25.06, for a total transaction of $409,856.30. Following the sale, the chief financial officer now directly owns 52,238 shares in the company, valued at $1,309,084.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Michael Brian Bell also recently made the following trade(s):
- On Tuesday, August 14th, Michael Brian Bell sold 12,500 shares of CareDx stock. The shares were sold at an average price of $16.84, for a total transaction of $210,500.00.
CareDx stock traded down $2.66 during trading hours on Friday, reaching $23.77. 772,976 shares of the stock were exchanged, compared to its average volume of 525,822. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -30.87 and a beta of 0.92. The company has a quick ratio of 1.83, a current ratio of 2.16 and a debt-to-equity ratio of 0.46. CareDx Inc has a twelve month low of $4.92 and a twelve month high of $29.60.
CareDx (NASDAQ:CDNA) last announced its quarterly earnings data on Thursday, August 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. The firm had revenue of $17.82 million for the quarter, compared to the consensus estimate of $15.30 million. CareDx had a negative net margin of 121.92% and a negative return on equity of 108.99%. On average, sell-side analysts expect that CareDx Inc will post -0.94 earnings per share for the current year.
Several equities analysts recently commented on the stock. Zacks Investment Research downgraded shares of CareDx from a “hold” rating to a “sell” rating in a research note on Monday, September 3rd. Piper Jaffray Companies upped their price target on shares of CareDx to $42.00 in a research note on Wednesday, September 5th. HC Wainwright restated a “neutral” rating and issued a $22.00 price target on shares of CareDx in a research note on Tuesday, September 18th. TheStreet downgraded shares of CareDx from a “c-” rating to a “d” rating in a research note on Monday, June 11th. Finally, BidaskClub upgraded shares of CareDx from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and two have issued a strong buy rating to the company’s stock. CareDx has an average rating of “Buy” and a consensus price target of $28.25.
A number of institutional investors have recently made changes to their positions in the business. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of CareDx by 7.9% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 87,748 shares of the company’s stock worth $1,074,000 after acquiring an additional 6,418 shares during the last quarter. Citadel Advisors LLC lifted its holdings in shares of CareDx by 37.5% in the second quarter. Citadel Advisors LLC now owns 26,216 shares of the company’s stock worth $321,000 after acquiring an additional 7,156 shares during the last quarter. Strs Ohio bought a new position in shares of CareDx in the second quarter worth about $116,000. Gagnon Advisors LLC lifted its holdings in shares of CareDx by 1.1% in the second quarter. Gagnon Advisors LLC now owns 965,894 shares of the company’s stock worth $11,823,000 after acquiring an additional 10,136 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY bought a new position in shares of CareDx in the second quarter worth about $139,000. Hedge funds and other institutional investors own 72.88% of the company’s stock.
CareDx, Inc, a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics.
Featured Article: Book Value Per Share in Stock Trading
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.